Health Catalyst vs Innodata
HCAT and INOD side by side, both in computer programming, data processing, and other computer related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCAT and INOD compare
Innodata is the larger company, worth 11 times as much as Health Catalyst ($1.2B against $114M).
Innodata grew revenue faster over the last twelve months (46.9% versus −13.9% for Health Catalyst).
Innodata keeps more of each dollar of sales as profit, with a net margin of 13.8% compared with −74.2% at Health Catalyst.
Innodata scores higher on the StockData Score (18 against 9 for Health Catalyst), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCAT | INOD |
|---|---|---|
| Size and price | ||
| Market cap | $114M | $1.2B |
| Share price | $1.51 | $35.46 |
| Change, 1 year | −38.6% | −42.8% |
| Change, 5 years | −96.7% | 390% |
| Beta (5Y) | 1.83 | 2.76 |
| Employees | 1,200 | 10K |
| StockData Score | ||
| Total score | 9 | 18 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 25.9× |
| P/S | 0.4× (better) | 3.5× |
| P/B | 0.8× (better) | 6.9× |
| EV/EBITDA | – | 16.2× |
| P/FCF | 4.4× (better) | 14.7× |
| FCF yield | 22.6% (better) | 6.8% |
| Fair value | $5.97 | $59.56 |
| Margin of safety | 74.7% (better) | 40.5% |
| Growth | ||
| Revenue growth (TTM) | −13.9% | 46.9% (better) |
| Revenue growth, 5Y average | 10.5% | 34.0% (better) |
| Net income growth (TTM) | – | 44.1% |
| EPS growth (TTM) | – | 34.3% |
| EPS growth, 5Y average | – | 115% |
| Profitability | ||
| Gross margin | 49.1% | – |
| Operating margin | −65.7% | – |
| Net margin | −74.2% | 13.8% (better) |
| FCF margin | 9.4% | 23.7% (better) |
| Return on equity | −84.6% | 35.4% (better) |
| Return on invested capital | −61.4% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.70 | 2.84 (better) |
| Altman Z-score | −9.02 | 10.30 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 69.4% | 57.1% |
| Held by insiders | 37.8% | 14.1% |
| Insider net buying, 12 months | −$94.9K (better) | −$161M |
| Short interest, % of float | 4.2% | 17.1% |
Go deeper
- HCAT stock overview
- HCAT income statement
- HCAT valuation and score
- INOD stock overview
- INOD income statement
- INOD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.